Log in

Relevant bibliographies by topics / Antineoplastika / Journal articles

To see the other types of publications on this topic, follow the link: Antineoplastika.

Journal articles on the topic 'Antineoplastika'

Author: Grafiati

Published: 28 June 2021

Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Antineoplastika.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Kreutzberger, Alfred, and Elfriede Kreutzberger. "Antineoplastika, 15. Mitt. Butylderivate der 5-Aminomethylenbarbitursäure." Archiv der Pharmazie 318, no. 9 (1985): 821–24. http://dx.doi.org/10.1002/ardp.19853180910.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Kreutzberger, Alfred, and Michael Sellheim. "Antineoplastika XVI [1]. 4-Alkyl-6-trifluormethyl-2-ureidopyrimidine." Journal of Fluorine Chemistry 27, no. 2 (1985): 203–12. http://dx.doi.org/10.1016/s0022-1139(00)84989-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Kreutzberger, Alfred, Peter Langner, and Jörg Stratmann. "Antineoplastika, 19. Mitt.: Darstellung vonN-[2-Chlor-4-diethylamino-(1,3,5-triazin-6-yl)]-aminosäuren." Archiv der Pharmazie 323, no. 12 (1990): 995–96. http://dx.doi.org/10.1002/ardp.19903231211.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Kreutzberger, Alfred, Peter Langner, and Jörg Stratmann. "Antineoplastika, 17. Mitt.1): Darstellung mono- und disubstituierter 2,4-Dichlor-6-diethylamino-1,3,5-triazine." Archiv der Pharmazie 324, no. 3 (1991): 173–76. http://dx.doi.org/10.1002/ardp.19913240308.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Burgaz, S., B. Karahalil, Z. Canli, et al. "Assessment of genotoxic damage in nurses occupationally exposed to antineoplastics by the analysis of chromosomal aberrations." Human & Experimental Toxicology 21, no. 3 (2002): 129–35. http://dx.doi.org/10.1191/0960327102ht230oa.

Full text

Abstract:

To estimate the genotoxic risk of occupational exposure to antineoplastic drugs, chromosomal aberration (CAs) frequencies in peripheral lymphocytes were determined for 20 nurses handling antineoplastics and 18 referents matched for age and sex. Urinary cyclophosphamide (CP) excretion rates, which are used as a marker for drug handling, were also measured on these nurses. We have observed significant frequencies of CAs (about 2.5-fold increase) including chromatid breaks, gaps, and acentric fragments for nurses handling antineoplastics as compared to control subjects (p<0.05, p<0.01, excl

APA, Harvard, Vancouver, ISO, and other styles

6

Kopjar, Nevenka, Davor Želježić, Vilena Kašuba, and Ružica Rozgaj. "Antineoplastic Drugs as a Potential Risk Factor in Occupational Settings: Mechanisms of Action at the Cell Level, Genotoxic Effects, and Their Detection Using Different Biomarkers." Archives of Industrial Hygiene and Toxicology 61, no. 1 (2010): 121–46. http://dx.doi.org/10.2478/10004-1254-61-2010-2025.

Full text

Abstract:

Antineoplastični Lijekovi Kao Čimbenik Rizika u Radnom Okolišu: Mehanizmi Djelovanja na Razini Stanice i Pregled Metoda za Otkrivanje Njihovih Genotoksičnih UčinakaU članku je prikazana osnovna podjela antineoplastičnih lijekova prema mehanizmima djelovanja na razini stanice. Objašnjeni su mehanizmi genotoksičnosti najvažnijih vrsta lijekova koji se primjenjuju u okviru uobičajenih protokola za liječenje zloćudnih novotvorina. Navedena je važeća klasifikacija antineoplastika prema kancerogenom potencijalu, podaci o mutagenom potencijalu te je prikazana njihova podjela u skladu s anatomsko-tera

APA, Harvard, Vancouver, ISO, and other styles

7

Guan, Xiaodong, Haishaerjiang Wushouer, Mingchun Yang, et al. "Influence of government price regulation and deregulation on the price of antineoplastic medications in China: a controlled interrupted time series study." BMJ Open 9, no. 11 (2019): e031658. http://dx.doi.org/10.1136/bmjopen-2019-031658.

Full text

Abstract:

BackgroundIn October 2012, the Chinese government established maximum retail prices for specific products, including 30 antineoplastic medications. Three years later, in June 2015, the government abolished price regulation for most medications, including all antineoplastic medications. This study examined the impacts of regulation and subsequent deregulation of prices of antineoplastic medications in China.MethodsUsing hospital procurement data and an interrupted time series with comparison series design, we examined the impacts of the policy changes on relative purchase prices (Laspeyres pric

APA, Harvard, Vancouver, ISO, and other styles

8

Hong, Samuel J., Edward C. Li, Linda M. Matusiak, and Glen T. Schumock. "Spending on Antineoplastic Agents in the United States, 2011 to 2016." Journal of Oncology Practice 14, no. 11 (2018): e683-e691. http://dx.doi.org/10.1200/jop.18.00069.

Full text

Abstract:

Purpose: Recent cancer drug approvals are lauded as being more effective with relatively fewer adverse effects, but these treatments come with a great cost to the US health care system. There is little information on recent trends in actual antineoplastic expenditures representative of the whole US health care system or by sector. Therefore, the objective of this study was to describe antineoplastic expenditures in the United States by year and sector. Methods: This was a retrospective, cross-sectional study of IQVIA (formerly QuintilesIMS) National Sales Perspective data for the period of Jan

APA, Harvard, Vancouver, ISO, and other styles

9

Olin, Jacqueline L., Olga Klibanov, Alexandre Chan, and Linda M. Spooner. "Managing Pharmacotherapy in People Living With HIV and Concomitant Malignancy." Annals of Pharmacotherapy 53, no. 8 (2019): 812–32. http://dx.doi.org/10.1177/1060028019833038.

Full text

Abstract:

Objective: To describe data with selected malignancies in people living with HIV (PLWH) and HIV in individuals affected by both conditions and to summarize drug-drug interactions (DDIs) with clinical recommendations for point-of-care review of combination therapies. Data Sources: Literature searches were performed (2005 to December 2018) in MEDLINE and EMBASE to identify studies of malignancies in PLWH in the modern era. Study Selection and Data Extraction: Article bibliographies and drug interaction databases were reviewed. Search terms included HIV, antiretroviral therapy, antineoplastic age

APA, Harvard, Vancouver, ISO, and other styles

10

S R, Vendra. "A Review on Venetoclax – An Antineoplastic Agent." Journal of Medical Science And clinical Research 05, no. 04 (2017): 20012–15. http://dx.doi.org/10.18535/jmscr/v5i4.45.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Galpin, A. J., and W. E. Evans. "Therapeutic drug monitoring in cancer management." Clinical Chemistry 39, no. 11 (1993): 2419–30. http://dx.doi.org/10.1093/clinchem/39.11.2419.

Full text

Abstract:

Abstract Several anticancer drugs display characteristics that make them suitable candidates for therapeutic drug monitoring (TDM), including substantial pharmacokinetic variability and a narrow therapeutic index. However, concentration-effect relationships (pharmacodynamics) of most antineoplastic agents have not been well defined, thus limiting the widespread clinical application of TDM for cancer chemotherapy. Strategic incorporation of pharmacokinetic studies during phase I-III clinical trials should facilitate the identification of concentration-effect relationships and the definition of

APA, Harvard, Vancouver, ISO, and other styles

12

Seal, Brian S., Jianying Yao, Jonathan K. Kish, Dana Stafkey-Mailey, and Michael Eaddy. "Evaluation of national treatment trends in ovarian cancer." Journal of Clinical Oncology 32, no. 30_suppl (2014): 204. http://dx.doi.org/10.1200/jco.2014.32.30_suppl.204.

Full text

Abstract:

204 Background: Evaluate patterns of care among women diagnosed with metastatic (M) and non-metastatic (NM) ovarian cancer (OvCa). Methods: Using MarketScan Commercial/Medicare databases, women ≥18 years old with primary diagnosis of OvCa continuously enrolled ≥6 months pre- and post-index diagnosis were selected. Patients receiving chemotherapy (chemo) prior to index diagnosis were excluded. Eligible patients were stratified into NM and M cohorts and M patients into those diagnosed with M ≤90 days (M1), 91-180 days (M2) and ≥ 181 days (M3) post index diagnosis. Types of treatments, time to in

APA, Harvard, Vancouver, ISO, and other styles

13

Mertens, W. C., L. J. Cassells, D. E. Brown, et al. "Chemotherapy ordering in a computerized physician order entry (CPOE) environment: A longitudinal analysis of defects from oncologist to patient." Journal of Clinical Oncology 24, no. 18_suppl (2006): 6040. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.6040.

Full text

Abstract:

6040 Background: While published data suggest low chemotherapy error rates, the rate of chemotherapy ordering process defects and who detects them remains uncertain. Methods: Outpatient treatment plans/orders were prospectively evaluated by pharmacy prior to preparation, then by nursing prior to administration. Data collected included the nature of defects, how detected, utility of regimen-specific care sets (facilitating antineoplastic dose calculation and adjunct agent selection), and patient impact. Results: Pharmacy recognized problems with 36% of orders (comprising 1,082 cycles/4,600 drug

APA, Harvard, Vancouver, ISO, and other styles

14

Das, Swagatika, H. Inci Gul, Umashankar Das, Jan Balzarini, Stephen G. Dimmock, and Jonathan R. Dimmock. "Novel Conjugated Unsaturated Ketones with Submicromolar Potencies Towards some Leukemic and Colon Cancer Cells." Medicinal Chemistry 15, no. 4 (2019): 430–38. http://dx.doi.org/10.2174/1573406414666181015142633.

Full text

Abstract:

Background: Cancer continues to be the major health burden worldwide. There is an urgent need for the development of novel antineoplastic compounds to treat this devastating condition. Various alkylating anticancer drugs have been employed in the clinic for treating cancers. Unsaturated conjugated ketones are a group of alkylators which are of significant interest as potent antineoplastic agents. Objective: The goal of this study is to discover unsaturated conjugated ketones which are novel potent cytotoxins displaying growth-inhibitory properties towards neoplasms and also to serve as cytotox

APA, Harvard, Vancouver, ISO, and other styles

15

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1197 (2008): 7. http://dx.doi.org/10.2165/00128415-200811970-00020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1197 (2008): 7–8. http://dx.doi.org/10.2165/00128415-200811970-00022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1197 (2008): 8. http://dx.doi.org/10.2165/00128415-200811970-00025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1198 (2008): 6. http://dx.doi.org/10.2165/00128415-200811980-00017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1199 (2008): 8. http://dx.doi.org/10.2165/00128415-200811990-00018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1201 (2008): 8. http://dx.doi.org/10.2165/00128415-200812010-00020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1202 (2008): 6–7. http://dx.doi.org/10.2165/00128415-200812020-00015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1203 (2008): 8–9. http://dx.doi.org/10.2165/00128415-200812030-00022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1203 (2008): 8. http://dx.doi.org/10.2165/00128415-200812030-00023.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1207 (2008): 8–9. http://dx.doi.org/10.2165/00128415-200812070-00021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1208 (2008): 7. http://dx.doi.org/10.2165/00128415-200812080-00022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1209 (2008): 8–9. http://dx.doi.org/10.2165/00128415-200812090-00025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1209 (2008): 8. http://dx.doi.org/10.2165/00128415-200812090-00027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1209 (2008): 9. http://dx.doi.org/10.2165/00128415-200812090-00030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1210 (2008): 7–8. http://dx.doi.org/10.2165/00128415-200812100-00019.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1211 (2008): 7–8. http://dx.doi.org/10.2165/00128415-200812110-00020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1212 (2008): 8. http://dx.doi.org/10.2165/00128415-200812120-00024.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1213 (2008): 8. http://dx.doi.org/10.2165/00128415-200812130-00019.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1216 (2008): 8. http://dx.doi.org/10.2165/00128415-200812160-00019.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1218 (2008): 7. http://dx.doi.org/10.2165/00128415-200812180-00018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1219 (2008): 7. http://dx.doi.org/10.2165/00128415-200812190-00018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1222 (2008): 7. http://dx.doi.org/10.2165/00128415-200812220-00019.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1223 (2008): 4–5. http://dx.doi.org/10.2165/00128415-200812230-00012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1225 (2008): 6. http://dx.doi.org/10.2165/00128415-200812250-00016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1228 (2008): 7. http://dx.doi.org/10.2165/00128415-200812280-00020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1228 (2008): 7–8. http://dx.doi.org/10.2165/00128415-200812280-00021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1320 (2010): 11. http://dx.doi.org/10.2165/00128415-201013200-00032.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1320 (2010): 12. http://dx.doi.org/10.2165/00128415-201013200-00035.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1323 (2010): 9. http://dx.doi.org/10.2165/00128415-201013230-00024.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1324 (2010): 11–12. http://dx.doi.org/10.2165/00128415-201013240-00026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1325 (2010): 8. http://dx.doi.org/10.2165/00128415-201013250-00022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1325 (2010): 8. http://dx.doi.org/10.2165/00128415-201013250-00023.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1328 (2010): 8. http://dx.doi.org/10.2165/00128415-201013280-00023.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1282 (2009): 10. http://dx.doi.org/10.2165/00128415-200912820-00032.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1282 (2009): 10. http://dx.doi.org/10.2165/00128415-200912820-00035.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

&NA;. "Antineoplastics." Reactions Weekly &NA;, no. 1283 (2010): 13. http://dx.doi.org/10.2165/00128415-201012830-00042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!